Drugs in the Pipeline
Dabigatran Comparable to Warfarin in DVT/PE Trial
Boehringer Ingelheim announced results from the RE-COVER II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).